Taiga Otsuka

Dr. Taiga Otsuka


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
FKFuta Koga
Futa Koga
YKYasunori Kawaguchi
Yasunori Kawaguchi
MSMototsugu Shimokawa
Mototsugu Shimokawa
KMKenichiro Murayama
Kenichiro Murayama
SNShunya Nakashita
Shunya Nakashita
KMKenji Mitsugi
Kenji Mitsugi

3 January 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
TSTaro Shibuki
Taro Shibuki
TMToshihiko Mizuta
Toshihiko Mizuta
MSMototsugu Shimokawa
Mototsugu Shimokawa
FKFuta Koga
Futa Koga
YUYujiro Ueda
Yujiro Ueda
TOTaiga Otsuka
Taiga Otsuka
Background: No reliable nomogram has been developed until date for predicting the survival in patients with unresectable pancreatic cancer undergoing treatment with gemcitabine plus nab–paclitaxel (GnP) or FOLFIRINOX. Methods: This analysis was conducted using clinical data of Japanese patients with unresectable pancreatic cancer undergoing GnP or FOLFIRINOX treatment obtained from a multicenter study (NAPOLEON study). A Cox proportional hazards model was used to identify the independent prognostic factors. A nomogram to predict 6–, 12–, and 18–month survival probabilities was generated, validated by using the concordance index (C–index), and calibrated by the bootstrapping method. And then, we attempted risk stratification for survival by classifying the patients according to the sum of the scores on the nomogram (total nomogram points). Results: A total of 318 patients were enrolled. A prognostic nomogram was generated using data on the Eastern Cooperative Oncology Group performance status, liver metastasis, serum LDH, serum CRP, and serum CA19–9. The C–indexes of the nomogram were 0.77, 0.72 and 0.70 for 6–, 12–, and 18–month survival, respectively. The calibration plot showed optimal agreement at all points. Risk stratification based on tertiles of the total nomogram points yielded clear separations of the survival curves. The median survival times in the low–, moderate–, and high–risk groups were 15.8, 12.8 and 7.8 months (P<0.05), respectively. Conclusions: Our nomogram might be a convenient and inexpensive tool to accurately predict survival in Japanese patients with unresectable pancreatic cancer undergoing treatment with GnP or FOLFIRINOX, and will help clinicians in selecting appropriate therapeutic strategies for individualized management.

27 March 2023 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
YIYasushi Ide
Yasushi Ide
TOTaiga Otsuka
Taiga Otsuka
MSMototsugu Shimokawa
Mototsugu Shimokawa
FKFuta Koga
Futa Koga
YUYujiro Ueda
Yujiro Ueda
TSTsuyoshi Shirakawa
Tsuyoshi Shirakawa
Background/Aim: Recent advances in chemotherapy have made significant progress in conversion surgery (CS) for unresectable pancreatic cancer (uPC). However, the success rate and efficacy of CS have not been fully demonstrated in patients with uPC treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP). Patients and Methods: We retrospectively reviewed the records of 318 patients with uPC who received FFX or GnP as first-line chemotherapy. The efficacy in the CS group, defined as undergoing complete resection after chemotherapy, was analyzed, and compared with the non-CS group; then, contributing factors to achieving CS were extracted. We also analyzed differences in the efficacy of CS between locally advanced pancreatic cancer (LAPC) and metastatic pancreatic cancer (MPC). Results: Overall, CS was achieved in 4.3% of cases, eight patients (13.3%) with LAPC and five (2.1%) with MPC. Contributing factors to CS were LAPC, no liver metastasis, CA19-9 ≤37, and chemotherapy response. After adjusting for these, overall survival was significantly better in the CS group than in the non-CS group [median of 32.9 vs. 11.3 months; adjusted hazard ratio (HR)=0.32; 95% confidence interval (CI)=0.14-0.70; p<0.01]. Median relapse-free survival duration after CS was 19.1 and 18.1 months in the LAPC-CS and MPC-CS group, respectively (p=0.84). The median post-conversion survival was 27.6 months in the entire CS group, 43.8 months in the LAPC-CS group and 21.3 months in the MPC-CS group. Conclusion: CS was achieved in 13.3% of LAPC and 2.1% of MPC cases. If possible, CS can markedly improve prognosis, even in MPC.

5 July 2021 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
HTHiroki Taguchi
Hiroki Taguchi
TOTaiga Otsuka
Taiga Otsuka
MSMototsugu Shimokawa
Mototsugu Shimokawa
SAShiho Arima
Shiho Arima
SHShinichi Hashimoto
Shinichi Hashimoto
TSTsuyoshi Shirakawa
Tsuyoshi Shirakawa
Background/Aim: The aim of the study was to evaluate gemcitabine plus nanoparticle albumin-bound paclitaxel (GnP) and FOLFIRINOX for recurrent pancreatic cancer (rPC) after resection. Patients and Methods: Forty-four patients with rPC and 211 with de novo metastatic pancreatic cancer (mPC) who received GnP or FOLFIRINOX as first-line chemotherapy were retrospectively analyzed. Results: On crude analysis, the median overall survival (OS) was significantly longer in the rPC group than in the mPC group (14.0 vs. 10.6 months, respectively; p=0.02). However, the difference was not significant on adjusted analysis using the Cox proportional hazards model (adjusted p=0.90). Patients receiving FOLFIRINOX (n=10) and GnP (n=34) in the rPC group had comparable OS (medians, 12.2 vs. 14.4 months, respectively; p=0.82) even after adjusting for covariates using the Cox model (adjusted p=0.18). Conclusion: The outcomes of patients in the rPC and mPC groups were comparable following chemotherapy. Both FOLFIRINOX and GnP may be reasonable options for treating rPC.

15 May 2015 in Diseases
Verified
Journal Article
Open access
PDF file
TOTaiga Otsuka
Taiga Otsuka
SNShunya Nakashita
Shunya Nakashita
KYKimihiko Yanagita
Kimihiko Yanagita
KAKeisuke Ario
Keisuke Ario
HKHiroaki Kawasoe
Hiroaki Kawasoe
TMToshihiko Mizuta
Toshihiko Mizuta
Sorafenib exerts modest antitumor activity in patients with advanced hepatocellular carcinoma (HCC), and radiological progressive disease (rPD) does not always correspond to so-called clinical progressive disease (cPD). We evaluated 101 patients who initiated sorafenib treatment for HCC and assessed post-progression survival (PPS) using the Cox proportional hazards model. PPS was calculated from the date of the first rPD until the date of death or the last follow-up. Using Cox model analysis of the 76 patients who experienced first rPD, we identified the Child-Pugh class, Eastern Cooperative Oncology Group performance status, the best antitumor response during treatment (using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1) and α-fetoprotein levels as independent factors affecting PPS. When these factors were used to define scores ranging from zero to five with a cutoff value of two, PPS of patients who received best supportive care (BSC) after rPD was not statistically significantly different from that of patients who received post-rPD therapy with scores ≥2 (p = 0.220). In contrast, the PPS for the post-rPD therapy group was significantly longer compared with the BSC patients with scores <2 (p < 0.001). Patients who scored ≥2 at their first rPD were judged cPD and as candidates for BSC.

1 April 2017 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
YKYasunori Kawaguchi
Yasunori Kawaguchi
TOTaiga Otsuka
Taiga Otsuka
WYWataru Yoshioka
Wataru Yoshioka
SNShotaro Noge
Shotaro Noge
Hirokazu TakahashiHirokazu Takahashi
Hirokazu Takahashi
TMToshihiko Mizuta
Toshihiko Mizuta